They all had a type of
ovarian tumor called a teratoma.
Not exact matches
Razqallah Hakem, a cancer biologist at the University of Toronto in Ontario, and his colleagues normally study a
tumor suppressor
called BRCA1, variants of which put women at high risk of breast and
ovarian cancer.
Importantly, elevated BRCA1 methylation was confined to patients diagnosed with so -
called high - grade serous
tumors, the most aggressive variant of
ovarian cancer, which also is the variant associated with BRCA1 mutations.
In a major breakthrough for
ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive
tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.
Surgeons gathered to focus on a quality improvement program to address a central issue in treating advanced
ovarian cancer — how to optimize surgery to achieve complete removal of all visible
tumor — also
called optimal resection.
The earliest and one of the most striking came from observations that the presence of infiltrating T cells (
called «
tumor - infiltrating lymphocytes,» or TILs) in
ovarian tumors is positively and strongly associated with improved survival of patients with
ovarian cancer [1].
Hargreaves brings her knowledge of biochemistry and epigenetic regulation to investigate a subunit of the SWI / SNF complex
called ARID1A, which is mutated in many solid
tumors, such as in
ovarian, bladder and colorectal cancers.
The approach developed by the MGH team starts with the engineered protein, which in this case fuses an antibody fragment targeting a protein
called mesothelin — expressed on the surface of such
tumors as mesothelioma,
ovarian cancer and pancreatic cancer — to a protein from the tuberculosis bacteria that stimulates the activity of dendritic and other immune cells.
A class of drugs
called EZH2 inhibitors are currently in clinical development for both hematological malignancies and solid
tumors and may be effectively targeted to epithelial
ovarian cancers overexpressing the CARM1 protein.